SecBot SecBot
PRESS-RELEASE ·Filed May 4, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong efficacy and safety data could drive near-term upside. Monitor for updates on the IMPACT trial and potential regulatory filings. Insider trading patterns and analyst upgrades may provide further signals.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.53
T+0 close · May 4, 2026 · via day close
Latest settled
+48.47%
T+60 · $11.18
Vs SPY
+46.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $7.53entry
  2. T+1 · 7mo ago −1.86%α −2.65% · $7.39
  3. T+5 · 6mo ago +37.32%α +34.38% · $10.34
  4. T+20 · 6mo ago +28.35%α +22.71% · $9.67
  5. T+60 · 4mo ago +48.47%α +46.62% · $11.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced 100% local disease control in evaluable patients from pooled first-in-human trials of Alpha DaRT for pancreatic cancer, presented at DDW 2026. The favorable safety and efficacy data in heavily pre-treated patients represent a significant milestone for the company's lead product candidate.

Key Facts

  • 100% local disease control in 19 evaluable patients (79% stable disease, 21% partial response)
  • Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
  • First presentation of Alpha DaRT at a major gastroenterology conference (DDW 2026)
  • Treatment delivered via EUS, designed for integration into standard GI workflow
  • Ongoing U.S. multicenter pancreatic cancer IMPACT trial

Financial Impact

Positive sentiment boost; potential future revenue if approved, but no current financial impact

Risk Factors

  • Data is from early-stage trials; larger studies may not replicate results
  • Alpha DaRT is not yet approved for commercial use in the U.S.
  • Biotech volatility; stock may have priced in expectations

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3286810

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026